BACKGROUND: Chronic venous insufficiency (CVI) represents a major global health problem with increasing prevalence and morbidity. CVI is due to an incompetence of the venous valves, which causes venous reflux and distal venous hypertension. Several studies have focused on the replacement of diseased venous valves using xeno- and allogenic transplants, so far with moderate success due to immunologic and thromboembolic complications. Autologous cell-derived tissue-engineered venous valves (TEVVs) based on fully biodegradable scaffolds could overcome these limitations by providing non-immunogenic, non-thrombogenic constructs with remodeling and growth potential. METHODS: Tri- and bicuspid venous valves (n=27) based on polyglycolic acid-poly-4-hydroxybutyrate composite scaffolds, integrated into self-expandable nitinol stents, were engineered from autologous ovine bone-marrow-derived mesenchymal stem cells (BM-MSCs) and endothelialized. After in vitro conditioning in a (flow) pulse duplicator system, the TEVVs were crimped (n=18) and experimentally delivered (n=7). The effects of crimping on the tissue-engineered constructs were investigated using histology, immunohistochemistry, scanning electron microscopy, grating interferometry (GI), and planar fluorescence reflectance imaging. RESULTS: The generated TEVVs showed layered tissue formation with increasing collagen and glycosaminoglycan levels dependent on the duration of in vitro conditioning. After crimping no effects were found on the MSC level in scanning electron microscopy analysis, GI, histology, and extracellular matrix analysis. However, substantial endothelial cell loss was detected after the crimping procedure, which could be reduced by increasing the static conditioning phase. CONCLUSIONS: Autologous living small-diameter TEVVs can be successfully fabricated from ovine BM-MSCs using a (flow) pulse duplicator conditioning approach. These constructs hold the potential to overcome the limitations of currently used non-autologous replacement materials and may open new therapeutic concepts for the treatment of CVI in the future.
BACKGROUND:Chronic venous insufficiency (CVI) represents a major global health problem with increasing prevalence and morbidity. CVI is due to an incompetence of the venous valves, which causes venous reflux and distal venous hypertension. Several studies have focused on the replacement of diseased venous valves using xeno- and allogenic transplants, so far with moderate success due to immunologic and thromboembolic complications. Autologous cell-derived tissue-engineered venous valves (TEVVs) based on fully biodegradable scaffolds could overcome these limitations by providing non-immunogenic, non-thrombogenic constructs with remodeling and growth potential. METHODS: Tri- and bicuspid venous valves (n=27) based on polyglycolic acid-poly-4-hydroxybutyrate composite scaffolds, integrated into self-expandable nitinol stents, were engineered from autologous ovine bone-marrow-derived mesenchymal stem cells (BM-MSCs) and endothelialized. After in vitro conditioning in a (flow) pulse duplicator system, the TEVVs were crimped (n=18) and experimentally delivered (n=7). The effects of crimping on the tissue-engineered constructs were investigated using histology, immunohistochemistry, scanning electron microscopy, grating interferometry (GI), and planar fluorescence reflectance imaging. RESULTS: The generated TEVVs showed layered tissue formation with increasing collagen and glycosaminoglycan levels dependent on the duration of in vitro conditioning. After crimping no effects were found on the MSC level in scanning electron microscopy analysis, GI, histology, and extracellular matrix analysis. However, substantial endothelial cell loss was detected after the crimping procedure, which could be reduced by increasing the static conditioning phase. CONCLUSIONS: Autologous living small-diameter TEVVs can be successfully fabricated from ovine BM-MSCs using a (flow) pulse duplicator conditioning approach. These constructs hold the potential to overcome the limitations of currently used non-autologous replacement materials and may open new therapeutic concepts for the treatment of CVI in the future.
Authors: Petra E Dijkman; Anita Driessen-Mol; Laura Frese; Simon P Hoerstrup; Frank P T Baaijens Journal: Biomaterials Date: 2012-03-31 Impact factor: 12.479
Authors: Dörthe Schmidt; Petra E Dijkman; Anita Driessen-Mol; Rene Stenger; Christine Mariani; Arja Puolakka; Marja Rissanen; Thorsten Deichmann; Bernhard Odermatt; Benedikt Weber; Maximilian Y Emmert; Gregor Zund; Frank P T Baaijens; Simon P Hoerstrup Journal: J Am Coll Cardiol Date: 2010-08-03 Impact factor: 24.094
Authors: Dörthe Schmidt; Josef Achermann; Bernhard Odermatt; Christian Breymann; Anita Mol; Michele Genoni; Gregor Zund; Simon P Hoerstrup Journal: Circulation Date: 2007-09-11 Impact factor: 29.690
Authors: Benedikt Weber; Jacques Scherman; Maximilian Y Emmert; Juerg Gruenenfelder; Renier Verbeek; Mona Bracher; Melanie Black; Jeroen Kortsmit; Thomas Franz; Roman Schoenauer; Laura Baumgartner; Chad Brokopp; Irina Agarkova; Petra Wolint; Gregor Zund; Volkmar Falk; Peter Zilla; Simon P Hoerstrup Journal: Eur Heart J Date: 2011-03-17 Impact factor: 29.983
Authors: Jason D Roh; Rajendra Sawh-Martinez; Matthew P Brennan; Steven M Jay; Lesley Devine; Deepak A Rao; Tai Yi; Tamar L Mirensky; Ani Nalbandian; Brooks Udelsman; Narutoshi Hibino; Toshiharu Shinoka; W Mark Saltzman; Edward Snyder; Themis R Kyriakides; Jordan S Pober; Christopher K Breuer Journal: Proc Natl Acad Sci U S A Date: 2010-03-05 Impact factor: 11.205
Authors: Philipp Kiefer; Felix Gruenwald; Joerg Kempfert; Heike Aupperle; Joerg Seeburger; Friedrich Wilhelm Mohr; Thomas Walther Journal: Ann Thorac Surg Date: 2011-07 Impact factor: 4.330
Authors: Gerrit J de Borst; Joep A W Teijink; Marlowe Patterson; Tino C Quijano; Frans L Moll Journal: J Endovasc Ther Date: 2003-04 Impact factor: 3.487
Authors: Fernando González-Pérez; Sergio Acosta; Stephan Rütten; Caroline Emonts; Alexander Kopp; Heinz-Werner Henke; Philipp Bruners; Thomas Gries; J Carlos Rodríguez-Cabello; Stefan Jockenhoevel; Alicia Fernández-Colino Journal: Front Bioeng Biotechnol Date: 2022-09-21